A longitudinal assessment by Ciccarone et al., 2020 (23), which included patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, breast cancer, and leukemia, found AMH levels fluctuated over time rather than a linear recovery trajectory. This evidence concerns the gene AMH and breast carcinoma.